The TWiVy team deconstructs CoronaVac, the inactivated SARS-CoV-2 vaccine produced by Sinovac Biotech, and production of multivalent camelid nanobodies that block infection with the virus and suppress selection of neturalization-resistant variants.

On this episode, a discussion of why modifying the dose schedule of the mRNA vaccines in the US is not a good idea, evidence that lower Ct values on hospital admission is associated with higher mortality, and dose-dependent response to SARS-CoV-2 infection of ferrets.

TWiV reviews additional data on the UK variant of SARS-CoV-2, the distinct variant spreading in South Africa, association of afucosylated antiviral IgG with severe COVID-19, approval of AstraZeneca vaccine in the UK, and winners of the pandemic poem contest.

TWiV reviews the latest data on the UK variant of SARS-CoV-2, including some properties of the variant and why it is being closely studied, development of liver cancer in a participant in a adenovirus-associated virus gene therapy trial, and answers to listener questions.

TWiV explains that COVID-19 is not harmless for young adults, FAA approval for Pfizer mRNA vaccine, lack of justification for the claim of reverse transcription of SARS-CoV-2 RNA and integration into the human genome, and lack of evidence for increased transmission by new variants in the UK.